WuXi Healthcare Ventures Joins $115M Series E Round In 23andMe

Mountain View, California-based DNA testing firm 23andMe, Inc. has completed US$115 million series E financing round led by Fidelity Management & Research Company, with participation from new investors including WuXi Healthcare Ventures.

Other investors include Casdin Capital, Illumina, New Enterprise Associates, MPM Capital, and Google Ventures, also joined the funding round, according to an announcement.

The company says it will use the proceeds to expand its operations and maximize the potential of its direct-to-consumer product in the U.S. and internationally.

WuXi Healthcare Ventures is the corporate venture capital arm of WuXi AppTec, and focuses on investing in life science companies with an emphasis on China and the U.S., according to information posted on its website.

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets